February 2024 in “Brain research bulletin” This study observed that inhibiting androgenic activity during early postnatal development significantly decreased body weight in female rats by day 90, while affecting food intake and fat distribution in both sexes based on the inhibited testosterone metabolic pathway.
1 citations
,
February 2024 in “Pharmacognosy Journal” In this study, fenugreek seed extract showed significant androgenic and spermatogenic effects in male rats, likely through inhibiting testosterone metabolism, without impacting cardiovascular health.
January 2025 in “European Journal of Pharmacology” This study found that forsythoside A, a compound from Forsythia suspensa, may counteract DHT-induced hair regrowth inhibition by selectively inhibiting TRPV3 channels.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.